AFTER CONSIDERING THE EFFICACY AND SAFETY OF TREMFYA^® FOR YOUR COMMERCIALLY INSURED ADULT PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA) EXPERIENCE

COMMERCIAL COVERAGE AS STRONG AS HUMIRA^® (adalimumab)—NO STEP EDIT REQUIRED^*†

When commercial insurance coverage is delayed >5 business days or denied, TREMFYA withMe offers eligible patients TREMFYA^® (guselkumab) at no cost until their commercial insurance covers the medication. See program requirements.

The information provided does not imply comparable safety or efficacy between products and only represents access information. Humira is a registered trademark of AbbVie Inc. Please refer to each product's prescribing information for indication(s), recommended dosing, and administration.

*These percentages may not represent 100% of formulary lives due to data limitations.

^†"As strong as"=absolute difference less than 5%.

^‡"Preferred" means TREMFYA^® can be accessed first-line (ie, step therapy is not required) and its formulary status is better than or equivalent to other products in the class.

When you choose TREMFYA^®, different patient-support programs may help patients get TREMFYA^®, depending on their coverage. Patients with government insurance may not have coverage for TREMFYA^®. Learn more about specific patient-support programs and eligibility requirements.

Collected in July 2022 and subject to change. This information does not provide advice or guarantee coverage or payment. Legal requirements and plan information can be updated frequently. We strongly recommend contacting the plan for more information about current coverage, restrictions, or prerequisites that may apply.

Source: Managed Markets Insight & Technology, LLC™, a trademark of MMIT, as of July 2022.

LOCAL COVERAGE OPTIONS FOR TREMFYA^® (guselkumab)

Explore TREMFYA^® coverage options in your area

TREMFYA^® coverage has changed in many regions—see where it has preferred first-line access without biologic step edits* by entering a ZIP code below.

*Requiring no step edits indicates a drug will be given first-line biologic access and will not require stepping through other biologic therapies.

CONTRAINDICATIONS
TREMFYA^® is contraindicated in patients with a history of serious hypersensitivity reaction to guselkumab or to any of the excipients.

WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarket use of TREMFYA^®. Some cases required hospitalization. If a serious hypersensitivity reaction occurs, discontinue TREMFYA^® and initiate appropriate therapy.

Infections
TREMFYA^® may increase the risk of infection. Treatment with TREMFYA^® should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

Consider the risks and benefits of treatment prior to prescribing TREMFYA^® in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA^® to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA^® until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)
Evaluate patients for TB infection prior to initiating treatment with TREMFYA^®. Initiate treatment of latent TB prior to administering TREMFYA^®. Monitor patients for signs and symptoms of active TB during and after TREMFYA^® treatment. Do not administer TREMFYA^® to patients with active TB infection.

Immunizations
Prior to initiating TREMFYA^®, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA^®.

ADVERSE REACTIONS
Most common (≥1%) adverse reactions associated with TREMFYA^® include upper respiratory infections, headache, injection site reactions, arthralgia, bronchitis, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.

The overall safety profile observed in patients with psoriatic arthritis is generally consistent with the safety profile in patients with plaque psoriasis, with the addition of bronchitis and neutrophil count decreased.

Please read the full Prescribing Information and Medication Guide for TREMFYA^®. Provide the Medication Guide to your patients and encourage discussion.

cp-82625v3